{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:00:45Z","timestamp":1771304445238,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the impact of prophylaxis with rIX\u2010FP, a fusion protein linking recombinant factor IX (FIX) with human albumin, on joint outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Joint outcomes were assessed in pediatric (&lt;12\u2009years) and adult\/adolescent (\u226512\u2009years) patients receiving rIX\u2010FP prophylaxis every 7, 10, or 14\u2009days; patients (&gt;18\u2009years) well\u2010controlled on a 14\u2010day regimen could switch to a 21\u2010day regimen. Target joints were defined as \u22653 spontaneous bleeds into a single joint within a 6\u2010month period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For adult\/adolescent (<jats:italic>n<\/jats:italic>\u2009=\u200963) and pediatric (<jats:italic>n<\/jats:italic>\u2009=\u200927) patients, median (Q1, Q3) annualized joint bleeding rate was 0.39 (0.00, 2.31), 0.80 (0.00, 2.85), 0.20 (0.00, 2.58), and 0.00 (0.00, 1.78) when treated with 7\u2010, 10\u2010, 14\u2010, or 21\u2010day prophylaxis. 50.0%, 38.9%, 45.5%, and 63.6% of adult\/adolescent patients had no joint bleeds when treated with 7\u2010, 10\u2010, 14\u2010, or 21\u2010day prophylaxis, respectively, and 40.7%, 37.5%, and 37.5% of pediatric patients had no joint bleeds when treated with 7\u2010, 10\u2010, or 14\u2010day prophylaxis. Ten adult and two pediatric patients developed target joints; all resolved by the end of the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prophylaxis with rIX\u2010FP produced low joint bleeding rates and provided excellent hemostatic efficacy in the treatment of joint bleeds. All target joints reported resolved with rIX\u2010FP prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14010","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T07:14:07Z","timestamp":1685085247000},"page":"293-299","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX \u22642%) receiving prophylaxis with rIX\u2010FP in the PROLONG\u20109FP clinical trial program"],"prefix":"10.1111","volume":"111","author":[{"given":"Hans\u2010Juergen","family":"Laws","sequence":"first","affiliation":[{"name":"Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health University of D\u00fcsseldorf  D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Tokyo Medical University Hospital  Tokyo Japan"},{"name":"Department of Blood Coagulation Ogikubo Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda","family":"Lopez\u2010Fernandez","sequence":"additional","affiliation":[{"name":"Haematology Department Complejo Hospitalario Universitario A Coru\u00f1a  A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[{"name":"CSL Behring  King of Prussia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Seifert","sequence":"additional","affiliation":[{"name":"CSL Behring  King of Prussia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Regional Reference Centre for Inherited Bleeding Disorders University Hospital of Parma  Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X16666160613114506"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S87659"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.04.030"},{"issue":"2","key":"e_1_2_10_6_1","first-page":"261","article-title":"Impact of pain and functional impairment in US adults with haemophilia: Patient\u2010reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P\u2010FiQ) study","volume":"24","author":"Kempton CL","year":"2017","journal-title":"J Thromb Haemost"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115709"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12108"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13449"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12375"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"issue":"4","key":"e_1_2_10_12_1","first-page":"659","article-title":"Long\u2010acting recombinant fusion protein linking coagulation factor IX with albumin (rIX\u2010FP) in children. Results of a phase 3 trial","volume":"116","author":"Kenet G","year":"2016","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14778"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1705116"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13896"},{"key":"e_1_2_10_17_1","first-page":"45","article-title":"Spontaneous bleeding and poor bleeding response with extended half\u2010life factor IX products: A survey of select US hemophilia treatment centers","volume":"3","author":"Malec LM","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.02.010"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000969"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12267"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02109.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1564032"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30193-4"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14036"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13360"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12902"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.02.030"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709521"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T21:08:44Z","timestamp":1703970524000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/ejh.14010"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14010","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"2022-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}